Walleye Capital’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$113K Sell
1,942
-48,708
-96% -$2.65M ﹤0.01% 3836
2026
Q1
$2.94M Buy
50,650
+35,845
+242% +$1.95M 0.01% 1161
2025
Q4
$683K Buy
+14,805
New +$662K ﹤0.01% 2729
2025
Q3
Sell
-362,610
Closed -$11.8M 4970
2025
Q2
$11.8M Buy
362,610
+256,644
+242% +$8.41M 0.05% 430
2025
Q1
$4M Sell
105,966
-42,390
-29% -$3.39M 0.02% 938
2024
Q4
$12.1M Buy
148,356
+90,140
+155% +$8.95M 0.03% 523
2024
Q3
$6.65M Buy
+58,216
New +$5.25M 0.01% 964
2024
Q2
Sell
-29,707
Closed -$2.03M 5900
2024
Q1
$2.03M Sell
29,707
-84,214
-74% -$5.83M ﹤0.01% 1985
2023
Q4
$7.15M Buy
+113,921
New +$5.92M 0.02% 872
2023
Q3
Sell
-59,041
Closed -$2.95M 5207
2023
Q2
$2.95M Sell
59,041
-28,842
-33% -$1.37M 0.01% 1054
2023
Q1
$3.29M Sell
87,883
-55,333
-39% -$2.35M 0.05% 462
2022
Q4
$6.87M Buy
143,216
+83,956
+142% +$3.29M 0.13% 203
2022
Q3
$1.42M Sell
59,260
-103,865
-64% -$2.63M 0.03% 737
2022
Q2
$3.55M Buy
163,125
+93,673
+135% +$2.17M 0.1% 230
2022
Q1
$1.68M Buy
+69,452
New +$1.52M 0.04% 419

Other funds holding PCVX

Walleye Capital's PCVX Position: Q2 2026 in Review

Walleye Capital reduced its Vaxcyte (PCVX) stake by 96% in Q2 2026, selling an estimated $2.65M and leaving 1,942 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #3836.

Walleye Capital first reported a position in PCVX in Q1 2022 and has held it in 15 quarters since. The position peaked at $12.1M in Q4 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Walleye Capital held 1,942 shares of Vaxcyte worth $113K as of Q2 2026.
  • Walleye Capital sold 48,708 Vaxcyte shares in Q2 2026, an estimated $2.65M.
  • Vaxcyte made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3836 holding.
  • Walleye Capital first reported a position in Vaxcyte in Q1 2022 and has held it in 15 quarters since.
  • Walleye Capital's Vaxcyte position peaked at $12.1M in Q4 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.